We assessed the impact of early antiretroviral treatment (ART) on human immunodeficiency virus (HIV) antibody detection by rapid tests in 44 individuals after several years of successful ART. HIV self-tests and point-of-care tests were negative in 30% and 7%-9% of cases, respectively. These data reinforce the message that patients should never be retested after entering HIV care.
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Prolonged antiretroviral treatment (ART) with undetectable viremia can lead to a decline in human immunodeficiency virus (HIV)-specific antibody titers, although seroreversion is rare when ART is initiated several years after infection [1, 2] . In contrast, nearly half of children starting ART within 12 weeks after birth are seronegative [3, 4] . Recently, in a cohort of highly exposed adults diagnosed at the time of primary HIV type 1 (HIV-1) infection (PHI) by means of nucleic acid testing (NAT) before seroconversion, 18% of participants were nonreactive with fourth-generation (4thG) immunoassays and 11% seroreverted after 24 weeks of ART [5] . This situation will become more frequent, as ART initiation during PHI is now recommended to improve clinical outcomes and prevent sexual transmission. Although retesting is not recommended, there are a number of situations where it may occur [3] [4] [5] , raising concerns on our ability to diagnose HIV infection with accuracy. In accordance with the World Health Organization guidelines, serological assays are widely used for testing strategies. In Europe and the United States, 4thG immunoassays are recommended for screening. Hence, PHI is usually diagnosed later than with NAT testing strategies. Treatment initiation is thereby deferred as well, which could differently affect the development of HIV-1-specific antibodies. Here we assessed the impact on serological test results of prolonged successful ART among adults first treated during PHI, in the setting of French national guidelines.
PATIENTS AND METHODS

Patients
The ongoing multicenter French National Agency for Research on AIDS and Viral Hepatitis (ANRS) Primary Infection Cohort (PRIMO) enrolls subjects with PHI in 95 French hospitals. PHI is confirmed by an incomplete Western blot (ie, absence of anti-p68 and/or anti-p34), or detectable p24 antigenemia, or detectable plasma viral load (VL) with a negative or weakly reactive enzyme-linked immunosorbent assay (ELISA), or an interval of <3 months between a negative and positive ELISA result. Clinical data, CD4 and CD8 T-cell counts, and plasma VL are determined at each site at months 1, 3, and 6 and every 6 months thereafter. Each laboratory participates in a national external quality control program. Samples of whole blood and plasma are collected and frozen at enrollment, at months 1, 3, 6, and 12, and every 12 months thereafter. The date of infection was estimated as previously described [6] . All participants were ART naive at enrollment. The decision to initiate treatment was guided by contemporary French recommendations at the time of PHI diagnosis, at the discretion of the patient's physician. The cohort was approved by the Paris-Cochin Ethics Committee, and all participants gave their written informed consent before enrollment.
We selected participants treated from PHI diagnosis for ≥36 months, without an interruption lasting >15 days, and with a sustained virological response (ie, VL <50 copies/mL within 9 months following ART initiation and then >90% of VL measurements <50 copies/mL during the first 36 months).
Methods
The HIV-specific serological response after >36 months on suppressive ART was evaluated by using the CE-certified (CE) self-test Autotest VIH (self-test), 2 point-of-care (POC) immunoassays (INSTI HIV-1/HIV-2 Rapid Antibody Test [INSTI] and VIKIA HIV1/2 [VIKIA]), and the 4thG ARCHITECT HIV Ag/Ab Combo immunoassay (4thG immunoassay, positive index threshold ≥1). These samples were also tested with Western blot using HIV-1 WESTERN BLOT (Bio-Rad).
During follow-up, cell-associated HIV DNA and ultrasensitive HIV VL levels were measured at a central laboratory, using, respectively, the real-time polymerase chain reaction GENERIC HIV-DNA assay (Biocentric), with a threshold of 60 copies/10 6 peripheral blood mononuclear cells, and the ultrasensitive real-time polymerase chain reaction technique GENERIC HIV (Biocentric), with a 1 copy/mL threshold. The cell-associated HIV DNA level was available for all patients at treatment initiation and on the day the sample was obtained for serological assays. Ultrasensitive HIV VL level was available for 28 participants, within ±12 months of the serological sample.
Statistical Analysis
Data are reported as median with interquartile range (IQR) or as frequencies. We compared the characteristics of individuals with negative vs positive self-tests, at treatment initiation and during treatment, using the χ 2 or Fisher exact tests for categorical data and the Wilcoxon rank-sum test for continuous data. Analyses were performed using R software (R Core Team 2015).
RESULTS
Forty-four participants (82% males) with a median age of 40 years were diagnosed at Fiebig stage II (32%), III (7%), IV (30%), V (20%), and VI (11%) ( Table 1) . At diagnosis, the median CD4 T-cell count was 372 cells/µL, median plasma VL was 5.3 log 10 copies/mL, and median cell-associated HIV DNA levels were 3.6 log 10 copies/10 6 peripheral blood mononuclear cells. ART was initiated a median of 43 days (range, 20-115 days) postinfection, corresponding to Fiebig stage II (5%), IV (37%), V (21%), or VI (37%). The HIV-specific serological response was evaluated after a median of 84 months (range, 36-204 months) of successful treatment. The characteristics of the 4 screening assays are shown in Table 2 . Overall, 13 participants tested negative with the self-test (30%), 4 with INSTI (9%), and 3 with VIKIA (7%). All the participants remained positive with the 4thG immunoassay (median index, 48 [range, 1.9-491]) but 7 (16%) had an index value <10. We looked for factors associated with self-test nonreactivity that were present at treatment initiation or during treatment ( Table 1 ). The time from infection to treatment initiation, type of first-line combination ART (boosted protease inhibitor vs another regimen), duration of viral suppression, CD4 T-cell count, VL, and cell-associated HIV DNA level were not associated with self-test nonreactivity. An association was found with the 4thG immunoassay index measured during treatment, which was weaker when the self-test was nonreactive (median index, 23 vs 60; P = .003). Self-test nonreactivity was also associated with the absence of anti-gp41 reactivity of these samples on Western blot (P = .01). The loss of serological reactivity might have been due to the decrease in replicative virus and a downsized reservoir. However, ultrasensitive HIV VL negativity during treatment (available for 28 participants) was not associated with self-test nonreactivity (P = .01). Likewise, no link was found between self-test nonreactivity and the reduction in cell-associated HIV DNA between treatment initiation and the day of sampling for serological assays. Of note, cell-associated HIV DNA remained detectable in 9 participants on the day of the negative self-test, and ultrasensitive HIV VL was positive in 5 participants.
Discussion
We assessed the impact of successful early treatment of HIV infection on postdiagnosis serological test results. We found that, respectively, 30% and 7%-9% of participants were seronegative with a self-test and with POC tests, while all remained positive with a 4thG immunoassay.
Recently, de Souza et al [5] observed seronegativity rates of 33%, 4%, and 17% with second-generation, third-generation, and 4thG immunoassays, respectively, after 24 weeks of ART in patients who started treatment during the acute infection. Here we confirm their findings in a setting closer to conventional screening and treatment guidelines, with diagnosis based on third-generation or 4thG immunoassays. Participants in the cohort studied by de Souza et al were diagnosed very early by NAT (mean, 19 days vs 43 days here), and most of them began treatment at Fiebig stage III or lower, compared to stage IV or higher in our study (ie, with an indeterminate or positive Western blot). This could explain the larger proportion of seronegative individuals in their study, as the humoral response would have been hampered earlier. The timing of treatment initiation is the factor most consistently associated with seroreversion in both adults and children [1] [2] [3] [4] [5] . Indirect associated markers such as a higher CD4 cell count or percentage [3, 5] , lower viral load [4, 5] , a less advanced Fiebig stage [5] , and a lower "detuned" assay result at baseline [2] suggest that the earlier the stage of HIV infection at treatment initiation and the more immature the anti-HIV immune response, the higher the likelihood of seroreversion. Interindividual variability in the pathophysiology of HIV infection [7] make it is less likely to find an association with the time, in days, between infection and treatment initiation, especially given the difficulties of precisely dating the infection.
Failure to detect HIV-specific antibodies is due to the effect of ART on the anti-HIV immune response and also on the characteristics of the chosen immunoassay. The 4 screening assays tested here detected antibodies directed to gp41. The observed absence of anti-gp41 antibodies on Western blot, along with the lower 4thG immunoassay index when the self-test is negative, suggests that the loss of anti-gp41 antibodies was responsible for the reduced reactivity of the rapid tests. The consistent positivity of 4thG immunoassays may be due to their intrinsic sensitivity and to the larger sample volume (100 μL vs 2.5 μL for self-test). Other studies have also shown an impact of early treatment initiation on the lack and/or loss of gp41 reactivity [5, [8] [9] [10] . In addition, anti-gp41 antibody titers fall gradually in individuals with sustained viral suppression on ART [8, 9, 11] . Thus, early treatment initiation and sustained viral suppression might act in concert over time to yield complete seronegativity. This issue should not call into question the use of gp41 proteins in screening assays. Indeed, ART has also been shown to reduce gp120-specific antibody titers [8] , as well as to yield seroreversion with screening assays based on gp120 and p24 proteins [5, 9] . ART initiation during PHI appears to shorten the half-life of gp160-specific immunoglobulin G3 (IgG3) by 1.5-fold, but its impact on gp41-specific IgG3 or on the more persistent immunoglobulin G1 is unclear [8] . Finally, gp41-specific antibodies are the first to arise during PHI [8] , and gp41 is an excellent candidate for serodetection because it includes an immunodominant epitope. The loss of HIV-specific antibodies is a consequence of viral suppression by ART and the resulting lack of antigen expression. Intermittent viral replication after ART initiation lessens the chances of seroreversion [3] . HIV-specific antibody levels might be a surrogate marker to evaluate the HIV replication burden and the viral reservoir. Among potential predictors of seroreversion, we found no association with the level of or decrease in cell-associated DNA, probably because of our limited sample size. However, a recent study showed a correlation between the size of the viral reservoir and antibody levels [9] . This interesting result might open new perspectives for evaluating the effectiveness of viral control in treated patients or the impact of functional-cure interventions on the latent reservoir.
Serological assays for HIV diagnosis have evolved considerably, allowing the detection of specific antibodies after as little as 3 weeks. Fourth-generation immunoassays shorten this window to 2 weeks with combined detection of p24 antigen [7] . These innovations have been subject to close scrutiny by both healthcare professionals and the public alike, regarding their sensitivity and specificity. This was also the case of rapid tests and self-tests, which were introduced more recently [12] and are now fully integrated in HIV testing services. The limits of each test must be borne in mind. A lack of sensitivity of self-test and POC test during PHI has already been reported [13] . Here we highlight another pitfall in test interpretation, which could mislead caregivers or users. Retesting after entering HIV care is not recommended by international guidelines but sometimes happens in practice. A recent survey conducted during a POC campaign in France by the community-based organization AIDES showed that 32% of retesters wanted to check the reliability of the rapid test and another 23% wanted to double-check their seropositivity in another setting than the hospital or laboratory (unpublished data). Free access to selftests is also leading to new practices such as partner testing for safer sexual decision making [14] , where retesting may happen eventually. The results of this and other studies [1] [2] [3] [4] [5] highlight the risk of negative serological results among people who started treatment during the acute infection, which should be kept in mind when providing counseling. In the setting of preexposure prophylaxis programs, the increasing number of persons who will start ART before antibody production begins could lead to a generation of seronegative HIV-infected persons [15] . 
